Salivary Gland Toxicity after Radioactive Iodine Therapy for Differentiated Thyroid Cancer Acute sialadenitis, Chronic sialadenitis, Radioactive Iodine Therapy, Differentiated Thyroid Cancer
Conditions
Interventions
Patient with Differentiated thyroid cancer who underwent Radioactive idodine.
Prevention
Patient with Differentiated thyroid cancer who underwent RAI
Sponsors
Department of Otolaryngology
Eligibility
Sex/Gender
All
Age
18 Years to 65 Years
Inclusion criteria
Inclusion criteria: 1. Adults aged 18-65 years old 2. Pathologically confirmed differentiated thyroid cancer 3. Planned for RAI therapy 4. Able to provide informed consent 5. Able to be contacted for follow-up
Exclusion criteria
Exclusion criteria: 1. Previous major salivary gland surgery 2. Known chronic sialadenitis, prior sialadenitis or Sjogren's syndrome 3. History of medication use or procedures that may interfere with salivary gland function 4. Prior head and neck radiotherapy 5. Incomplete baseline data
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| incidence of acute sialadenitis and chronic salivary dysfunction day 7 ,Day 14 ,3 months , 6 months structed questionaire and clinical examination | — |
Secondary
| Measure | Time frame |
|---|---|
| clinical and treatment-related factors associated with acute sialadenitis and chronic salivary gland dysfunction. 6 months logistic regression models,acute sialadenitis is associated with later chronic dysfunction. 6 months logistic regression models,effect of chronic dysfunction on salivary-related quality of life 6 months structed questionaire | — |
Countries
Thailand
Contacts
Public ContactThananya Onmun
Faculty of Medicine Ramathibodi Hospital Mahidol University
Outcome results
None listed